by Massimo Sandal (Agenzia Zoe)
Takeaway messages
-
LentiGlobin gene therapy improves quality of life (QoL), pain and fatigue in sickle cell disease (SCD) up to 24 months after treatment.
Why this matters
by Massimo Sandal (Agenzia Zoe)
Takeaway messages
LentiGlobin gene therapy improves quality of life (QoL), pain and fatigue in sickle cell disease (SCD) up to 24 months after treatment.
Why this matters
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.
Create a Free Account I have an account